Actelion Pharmaceuticals Ltd.

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage cardiovascular pharmaceutical company focused on developing drugs for unmet needs in thrombosis and cardiac rhythm control, and as Chief Medical Officer at Gemphire Therapeutics, Inc. He also serves as Chairman of the Advisory Board for Coagulation Sciences LLC. Previously, Dr. Golden held senior roles at Pfizer, Actelion, Eisai, Mesoblast, and others, with a long-standing focus on cardiovascular and hematologic drug development. “We are delighted to welcome Dr. Golden to our Board,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Lee’s deep experience in late-stage clinical development, particularly in cardiovascular medicine and anticoagulation, is highly aligned with our mission to deliver safer, more predictable anticoagulant options for patients with significant unmet needs. His track record in guiding therapies through clinical development and regulatory pathways will be invaluable as we continue to advance tecarfarin and our broader pipeline.” “Cadrenal Therapeutics is working in an area of high clinical importance, where better anticoagulation options could meaningfully impact outcomes for patients with complex cardiovascular conditions,” said Dr. Golden. “I look forward to working with the Board and the leadership team to help guide the Company’s strategy and clinical programs as we seek to bring differentiated therapies to patients and create value for shareholders.” Dr. Golden has more than 25 years of industry experience, with increasing responsibilities, managing global, cross-functional teams responsible for creating and deploying strategic and clinical development plans. He has extensive experience across multiple therapeutic areas and with orphan diseases. Dr. Golden received a B.S. from the University of Michigan and an MD from New York University School of Medicine, where he also completed his Internal Medicine residency. He then completed Fellowships in Cardiology at the University of Miami and Interventional Cardiology at George Washington University Hospital, where he also served as an adjunct instructor. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company with a mission to develop novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy. We bridge these gaps by developing novel and differentiated anticoagulants, or blood thinners, designed to provide greater predictability, increased stability, more precise control, and fewer bleeding complications. We currently have two clinical-stage assets: tecarfarin, an oral vitamin K antagonist (VKA) for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. By targeting underserved patient populations and advancing therapies designed for both chronic and acute use, we aim to reshape standards of care in anticoagulation. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding developing transformative therapeutics to overcome current gaps in anticoagulation therapy, the expected contribution of Dr. Golden and continuing to advance tecarfarin and the Company’s broader pipeline. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to overcome current gaps in anticoagulation therapy, Dr. Golden’s ability to help guide the Company’s strategy and clinical programs, the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. For more information, please contact: Lytham Partners, LLCRobert Blum, Managing Partner602-889-9700CVKD@lythampartners.com

iStock, Sean Pavone The Basel area is home to over 800 life sciences companies, including Novartis and Roche, according to nonprofit Basel Area Business & Innovation. The nonprofit’s CEO and a BeOne Medicines executive discuss the location’s evolution, advantages and future. Basel, Switzerland, has long been known as the place where Novartis and Roche are headquartered, but its reputation has expanded well beyond that, according to Basel Area Business & Innovation CEO Christof Klöpper. “It has transformed itself into an ecosystem with many players from a city of Roche, Novartis only,” he told BioSpace . The Basel area is home to over 800 life sciences companies and 33,000 employees, according to Basel Area Business & Innovation , which helps startups, institutions and companies find business success in the Basel area. High-pro in the region include Abbott, Bayer, Boehringer Ingelheim, Johnson & Johnson, Lonza, Moderna and Syngenta. Klöpper said one reason for the evolution is that American businesses have entered the European market by setting up company or regional headquarters in the area. Companies have also built a presence in Basel through mergers and acquisitions, he added, citing J&J as an example. The New Brunswick, New Jersey–based pharma in 2017 acquired Actelion, headquartered near Basel, for $30 billion. Rising Entrepreneurship Startups and spinoffs have also played a role in the evolution, according to Klöpper, because there’s an active academic scene in Switzerland, which he said has some of the best universities in continental Europe. Those schools include research-oriented University of Basel, which emphasizes life sciences and medicine. Klöpper attributed Basel becoming more entrepreneurial in part to Novartis and Roche bringing international employees—and therefore Americans’ entrepreneurship attitude—to the area. It’s now acceptable to not only form a startup but also to have it fail, he noted. Klöpper said that hasn’t always been a European way of doing business, as failure can be seen as negative, particularly in a German-speaking environment like Switzerland. “So, it’s OK to fail with one if you do it better with the next one,” he said of the cultural change. “This I’ve always admired in U.S. entrepreneurship.” Some scientists and entrepreneurs get help launching their businesses from BaseLaunch, a Basel-based biotech accelerator and incubator that provides assistance from inception to Series A funding. It provides financing of up to $500,000 per venture. Since 2018, according to Basel Area Business & Innovation, BaseLaunch has supported 24 ventures, and nine portfolio companies have raised over $800 million total. Their average first VC round was over $28 million per company. In addition to startups and spinoffs, the Basel area is also home to medium-sized businesses, including up-and-coming midsized biopharmas such as Anaveon, BeOne Medicines (formerly BeiGene), Idorsia, LifeMine Therapeutics and T3 Pharmaceuticals, according to Basel Area Business & Innovation. BeOne, a global oncology biopharma, established its European headquarters in Basel in 2018 to leverage the region’s deep pool of scientific talent and partnership opportunities, according to Aaron Rosenberg, chief financial officer. He told BioSpace in written interview responses that earlier this year, the company redomiciled its global entity from the Cayman Islands to Basel to strengthen its roots in the world-class global life sciences hub. “It is a thriving global center for life sciences, combining deep pharmaceutical roots with a rapidly growing biotech and innovation community,” Rosenberg said. “The region brings together world-class research institutions, major industry leaders, and a highly skilled international workforce, fostering collaboration and continuous scientific advancement.” The region brings together world-class research institutions, major industry leaders, and a highly skilled international workforce, fostering collaboration and continuous scientific advancement. Aaron Rosenberg, chief financial officer, BeOne Medicines Business Advantages of Basel There are several reasons Basel is a good location for life sciences businesses and entrepreneurs, according to Klöpper and Rosenberg. One Klöpper shared is that the city helps businesses deal with the complexity of the European market, where factors such as languages as well as payer systems, which affect product reimbursement, can be challenging. He explained that Basel is advantageous because it lies in three countries—France, Germany and Switzerland—and therefore has people who speak multiple languages and understand multiple systems. Rosenberg said Switzerland’s central position ensures that life sciences companies have a robust network of connections across the continent and globally and eases entry into international markets. “This positioning provides access to exceptional talents, infrastructure, networks, and partnership opportunities essential for business and pipeline development,” he said. Another advantage of the Basel area, according to Klöpper, is that it’s easy to work with local authorities, such as tax or immigration specialists, to set up a business because they understand life sciences. For example, he said, “If you have to set up a lab, people will understand how to set up a lab. It’s nothing that they haven’t done hundreds of times.” The Basel area also has a fantastic labor pool given the talent coming from its pharmas and universities, according to Klöpper. He noted that early on, U.S. companies that started doing business in Basel were surprised at how easily they filled open positions with good people. Klöpper said they may have benefited from the groundwork laid by Roche and Novartis, as the employers gave many employees good job experience, creating a fantastic labor market for other organizations. Challenges in Basel: Competition for Talent, Costs There are some challenges for life sciences companies in Basel, according to Klöpper and Rosenberg. One Rosenberg noted is that competition for talent is high, given the concentration of leading biopharma companies in the area. Another, he said, is that real estate and living expenses can be significant. Klöpper also commented on cost issues, noting that the cost of living is higher in Switzerland than in other European regions. That said, he also highlighted that the country has some of the highest salaries in Europe, which is reflected in a Euronews analysis this year. Using Eurostat and OECD data for 2023, Euronews found the average full-time adjusted salary per month in Switzerland is €8,104, which is about $9,308, making it the highest-paying country in Europe. Life sciences professionals can optimize their situation by receiving a Swiss salary while not living on the Swiss side, Klöpper advised. As an example, he noted that people living nearby in France can have a very nice house with a nice garden at a decent cost. The Livingcost cost of living calculator supports his recommendation, finding that the average cost of living in France is 46% less expensive than in Switzerland. Life sciences professionals who do choose to live in Basel will have a good quality of life, Klöpper noted. He pointed to factors such as a safe environment where young children often travel to school alone and fantastic healthcare at low cost. Those benefits tend to make an impression on U.S. life sciences professionals who move to Basel, according to Klöpper. “Due to the quality of life, quite a share of them in the end stay, at least until the end of their professional career,” he said. Looking Ahead: Continued Growth Expected Klöpper and Rosenberg have a positive outlook for the Basel area’s life sciences scene five years from now. Klöpper expects more startups and international companies to come in and hopes a recent trend of private investment in research and development institutes continues. Rosenberg said Basel’s role as one of the leading global life sciences centers should keep expanding. “The region is well positioned to evolve beyond its traditional pharmaceutical base into a broader innovation hub, encompassing biotechnology, digital health, and data-driven medicine,” he said. “We can also anticipate increased collaboration between academia, startups, and established companies will drive new discoveries and sustain the region’s leadership in advancing human health.” Want more job market insights?  Subscribe to  Career Insider  to receive our quarterly life sciences job market reports, career advice and more.

Pulmonary Edema revenue is expected to grow at a CAGR of 7.8 % from 2025 to 2032, reaching nearly USD 12.04 bn by 2032. Surging heart failure, chronic lung disorders, and trauma cases are propelling the Pulmonary Edema Market, with advanced therapies and diagnostics driving global healthcare innovation.” — Navneet Kaur MIAMI, FL, UNITED STATES, October 16, 2025 / EINPresswire.com / -- Explore the booming Pulmonary Edema Market , valued at USD 6.6 Bn in 2024 and set to reach USD 12.04 Bn by 2032. Discover key growth trends, rising cardiovascular disease cases, advanced diagnostics, oxygen therapy, gene therapies, and market insights driving global expansion and investment opportunities. Pulmonary Edema Market Overview: Pulmonary Edema Market, valued at USD 6.6 Bn in 2024 and projected to reach USD 12.04 Bn by 2032, is booming due to rising cardiovascular diseases, heart failure, chronic lung disorders, and trauma-related injuries. North America leads with advanced healthcare and key players like Pfizer, Novartis, ResMed, and AstraZeneca driving innovation through FDA approvals, gene therapies, and strategic acquisitions. Emerging markets such as China and India offer growth opportunities, while AI-assisted diagnostics, oxygen therapy, and novel treatments enhance patient outcomes, making the market a high-growth, innovation-driven global healthcare segment. Pulmonary Edema Market Set to Skyrocket as Cardiovascular Diseases and Trauma Surge – Advanced Treatments and Diagnostics Drive Explosive Growth Pulmonary Edema Market is set to surge as the global prevalence of cardiovascular diseases (CVDs) skyrockets. Heart attacks, strokes, and hypertension contribute to over 16.8 million deaths annually worldwide, driving urgent demand for effective pulmonary edema management and treatment solutions. Adding to the challenge, road accidents causing chest injuries claim 1.19 million lives each year, particularly among young adults, often leading to acute pulmonary complications. This growing healthcare burden is pushing hospitals, clinics, and home care providers to adopt advanced diagnostics, oxygen therapy, mechanical ventilation, and novel treatment options, creating dynamic growth opportunities in the Pulmonary Edema Market. 👉 Access the full Research Description at: https://www.stellarmr.com/report/req_sample/pulmonary-edema-market/2673 Pulmonary Edema Market Poised for Explosive Growth as Aging Population Drives Surge in Heart, Kidney, and Cardiovascular Cases Pulmonary Edema Market is poised for rapid growth as the global population ages, driving higher incidence of heart, kidney, and cardiovascular conditions, key risk factors for pulmonary edema. With age-related diseases on the rise, healthcare systems face growing demand for advanced pulmonary edema treatments, diagnostics, and management solutions. This demographic shift presents a massive growth opportunity, positioning the Pulmonary Edema Market as one of the most dynamic and fast-evolving segments in global healthcare. Pulmonary Edema Market Faces High-Stakes Challenges: Rising Costs, Access Gaps, and Treatment Risks Spark Urgent Need for Innovation Pulmonary Edema Market is expanding rapidly, but significant challenges and risks remain. High treatment costs, limited access to advanced diagnostics and therapies in developing regions, and potential side effects of medications could hinder market growth. Additionally, disparities in healthcare infrastructure and regulatory hurdles pose obstacles for timely patient care. To navigate these risks, stakeholders are advised to invest in telemedicine, remote monitoring solutions, and innovative treatment protocols, ensuring improved patient outcomes while capitalizing on the market’s growth potential. Pulmonary Edema Market Set to Soar: Cardiogenic and Non-Cardiogenic Cases Drive Demand for Advanced Diagnostics and Innovative Treatments Pulmonary Edema Market is witnessing rapid growth across disease types, diagnostics, and treatments. Cardiogenic pulmonary edema, linked to heart failure, coronary artery disease, and cardiomyopathy, dominates, affecting millions in the U.S. with high mortality, while non-cardiogenic pulmonary edema, caused by lung injury, infections, trauma, or high-altitude exposure, drives demand for oxygen therapy, mechanical ventilation, and innovative medications. Advanced diagnostics, including chest X-rays, CT scans, and AI-assisted lung ultrasounds, enable early detection, while hospitals, clinics, and ambulatory surgical centers provide critical care. Key Pulmonary Edema Market Trends: Rising Risk Factors and Growth Opportunities in Emerging Economies Increasing Prevalence of Underlying Conditions: A growing incidence of heart failure, cardiovascular diseases, and chronic lung disorders is driving expansion in the Pulmonary Edema Market, boosting demand for advanced treatments and diagnostics. Market Expansion in Emerging Economies: Rising health insurance coverage in countries like China and India is enhancing patient access to pulmonary edema treatments, driving significant market growth. Key Developments in the Pulmonary Edema Market: Strategic Acquisitions and Innovative Collaborations ResMed and Propeller Health Acquisition: In April 2023, ResMed acquired Propeller Health, boosting remote monitoring and data-driven care for pulmonary edema. AstraZeneca and BioNTech Collaboration: In March 2023, AstraZeneca partnered with BioNTech to develop novel therapies targeting pulmonary edema linked to lung cancer. 👉 Access the full Research Description at: https://www.stellarmr.com/report/req_sample/pulmonary-edema-market/2673 North America Dominates Pulmonary Edema Market: Rising Hospitalizations and High Mortality Highlight Urgent Need for Advanced Treatments Pulmonary Edema Market is dominated by North America, driven by a well-developed healthcare sector and high per capita spending. Acute cardiogenic pulmonary edema accounts for 1 million hospital admissions annually in the U.S., with high mortality rates, while England and Wales report over 67,000 admissions from acute heart failure. This significant healthcare burden underscores the urgent need for advanced treatment strategies, effective management, and improved patient outcomes, highlighting key growth opportunities in diagnostics and therapeutics. Pulmonary Edema Market Soars: Pfizer, Novartis, and Verve Drive Innovation with FDA Approvals and Cutting-Edge Gene Therapies Leading companies like Pfizer, Novartis, Medtronic, Siemens Healthineers, and BD are advancing pulmonary edema treatments through innovative therapies and clinical trials. Novartis secured FDA approval for Entresto targeting heart failure with preserved ejection fraction (HFpEF), while Verve Therapeutics initiated Phase 1b trials for VERVE-101, a promising gene therapy for pulmonary edema. These developments highlight a surge in cutting-edge treatments and market opportunities, offering hope for improved patient outcomes and reduced mortality. Key Players in the Pulmonary Edema Market North America Pfizer Inc. (USA) ARGON MEDICAL (USA) Edwards Lifesciences Corporation (USA) BD (Becton, Dickinson and Company) (USA) Abbott Laboratories (USA) Johnson & Johnson (USA) Merck & Co. (USA) GE Healthcare (USA) ResMed (USA) United Therapeutics Corporation (USA) Boehringer Laboratories (USA) Medtronic (USA) AstraZeneca (UK) Europe Bayer AG (Germany) Boehringer Ingelheim (Germany) Siemens Healthcare GmbH (Germany) Fresenius Medical Care (Germany) Novartis AG (Switzerland) Roche Holding AG (Switzerland) Actelion Pharmaceuticals Ltd. (Switzerland) Sanofi S.A. (France) Chiesi Farmaceutici (Italy) Koninklijke Philips N.V. (Netherlands) GlaxoSmithKline plc (UK) Asia Pacific Lupin Pharmaceuticals (India) Hitachi Medical Corporation (Japan) Canon Medical Systems Corporation (Japan) Vitaltec Corporation (Taiwan) Analyst Perspective: Global Pulmonary Edema Market is set for strong growth, driven by rising cardiovascular diseases, aging populations, and trauma cases. North America leads, while China and India offer growth opportunities. Key players like Pfizer, Novartis, ResMed, AstraZeneca, and Medtronic are expanding the market via FDA approvals, innovative therapies, acquisitions, and collaborations. Advanced diagnostics, AI imaging, oxygen therapy, and gene therapies are enhancing outcomes, positioning pulmonary edema as a high-growth, innovation-driven healthcare segment. FAQ: Q1: What is the Pulmonary Edema Market size and growth forecast? A1: The global Pulmonary Edema Market is valued at USD 6.6 Bn in 2024 and projected to reach USD 12.04 Bn by 2032 at a CAGR of 7.8%. Q2: What are the key drivers of Pulmonary Edema Market growth? A2: Rising cardiovascular diseases, heart failure, chronic lung disorders, trauma-related injuries, and aging populations are driving market expansion. Q3: Who are the major players in the Pulmonary Edema Market? A3: Leading companies include Pfizer, Novartis, ResMed, AstraZeneca, Medtronic, Siemens Healthineers, and BD, driving innovation through FDA approvals, gene therapies, and strategic collaborations. Maximize Market Research is launching a subscription model for data and analysis in the Dental Materials market https://www.mmrstatistics.com/markets/512/topic/833/pharmaceuticals Related Reports: Pulmonary Edema Market: https://www.stellarmr.com/report/pulmonary-edema-market/2673 Ureteral Obstruction Market: https://www.stellarmr.com/report/ureteral-obstruction-market/2614 Pleurisy Market: https://www.stellarmr.com/report/pleurisy-market/2612 Anti-aging Cosmetics Market: https://www.stellarmr.com/report/anti-aging-cosmetics-market/2562 Continence Care Products Market: https://www.stellarmr.com/report/continence-care-products-market/2483 About Stellar Market Research: Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies. Lumawant Godage Stellar Market Research + +91 9607365656 email us here Visit us on social media: LinkedIn Instagram X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.